ManRos Therapeutics Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 1

ManRos Therapeutics General Information

Description

Operator of a biotechnology company intended to offer treatments against cystic fibrosis, neurodegenerative, and renal diseases. The company specializes in the research and development of small-molecule drugs against severe pathologies, such as solid tumors and leukemia, including polycystic kidney disease, enabling medical practitioners to get molecules at a reduced cost with the collaboration of industrial experts.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • LD Presqu'ile De Perharidy Building 1
  • 29680 Roscoff
  • France
+33 02
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • LD Presqu'ile De Perharidy Building 1
  • 29680 Roscoff
  • France
+33 02

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ManRos Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Secondary Transaction - Private 01-Jun-2025 Completed Clinical Trials - Phase 2
6. Later Stage VC 23-May-2017 Completed Clinical Trials - Phase 2
5. Later Stage VC 15-Sep-2015 Completed Clinical Trials - Phase 2
4. Later Stage VC 01-Jul-2014 Completed Startup
3. Early Stage VC 01-Jun-2011 Completed Startup
2. Accelerator/Incubator 01-Jan-2008 Completed Startup
1. Accelerator/Incubator 01-Jan-2007 Completed Startup
To view ManRos Therapeutics’s complete valuation and funding history, request access »

ManRos Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
To view ManRos Therapeutics’s complete cap table history, request access »

ManRos Therapeutics Patents

ManRos Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4268824-A1 Imidazo[2,1-f][1,2,4]triazine derivatives useful as a medicament Inactive 26-Apr-2022
AU-2020242304-A1 Roscovitine analogues and use thereof for treating rare biliary diseases Inactive 20-Mar-2019
CA-3133409-A1 Roscovitine analogues and use thereof for treating rare biliary diseases Pending 20-Mar-2019
EP-3941476-A2 Roscovitine analogues and use thereof for treating rare biliary diseases Active 20-Mar-2019
EP-3941476-B1 Roscovitine analogues and use thereof for treating rare biliary diseases Active 20-Mar-2019 A61K31/52
To view ManRos Therapeutics’s complete patent history, request access »

ManRos Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ManRos Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Agoranov Accelerator/Incubator Minority
To view ManRos Therapeutics’s complete investors history, request access »

ManRos Therapeutics FAQs

  • When was ManRos Therapeutics founded?

    ManRos Therapeutics was founded in 2007.

  • Where is ManRos Therapeutics headquartered?

    ManRos Therapeutics is headquartered in Roscoff, France.

  • What is the size of ManRos Therapeutics?

    ManRos Therapeutics has 5 total employees.

  • What industry is ManRos Therapeutics in?

    ManRos Therapeutics’s primary industry is Biotechnology.

  • Is ManRos Therapeutics a private or public company?

    ManRos Therapeutics is a Private company.

  • What is ManRos Therapeutics’s current revenue?

    The current revenue for ManRos Therapeutics is .

  • How much funding has ManRos Therapeutics raised over time?

    ManRos Therapeutics has raised $7.26M.

  • Who are ManRos Therapeutics’s investors?

    Agoranov has invested in ManRos Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process